Retatrutide
Also known as GLP-3 triple agonist
GIP/GLP-1/glucagon triple receptor agonist
A triple-receptor incretin analog reported to produce the largest weight reductions seen in this class of research compounds.
How it works
Retatrutide is studied as a triple agonist acting on GIP, GLP-1, and glucagon receptors. The addition of glucagon receptor activity distinguishes it from dual agonists, since glucagon signaling is associated with increased energy expenditure and hepatic fat mobilization rather than only appetite suppression.
The GLP-1 and GIP components behave similarly to other incretin research compounds, slowing gastric emptying and modulating insulin release in a glucose-dependent manner. This combination is thought to reduce the risk of hypoglycemia compared with insulin secretagogues that are not glucose-dependent.
Because glucagon receptor activation increases hepatic glucose output in isolation, researchers note that the net metabolic effect depends on the balance across all three receptors. Trial data to date report weight reductions and reductions in hepatic fat fraction that exceed those seen with dual agonists at comparable trial stages.
What research has shown
Phase 2 data reported ~17% weight reduction at 24 weeks and ~24% at 48 weeks at the highest dose, with notable reductions in hepatic fat fraction.
Reported ranges in the literature
Low end
1 to 2 mg weekly (initiation)
Optimal
4 to 8 mg weekly
High end
12 mg weekly, the top dose in reported trials
Frequency reported in the literature: Once weekly. Note: Heart-rate increase and GI effects scale with dose in reported data.
Frequently asked questions
What is retatrutide?
Retatrutide is a triple receptor agonist activating GIP, GLP-1, and glucagon receptors, studied in the context of body weight and metabolic research.
How does retatrutide differ from tirzepatide?
Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide adds glucagon receptor activity, which researchers associate with greater reported weight reduction and hepatic fat change in early trial phases.
What does the phase 2 research show?
Published phase 2 data report roughly 17 percent weight reduction at 24 weeks and roughly 24 percent at 48 weeks at the highest studied dose, alongside meaningful reductions in liver fat fraction.
Are there other reported effects in the literature?
Trial reports note dose-dependent increases in heart rate and gastrointestinal effects, both of which researchers track closely during titration phases.
How long are research blocks typically?
Reported trial durations extend to 48 weeks or longer, reflecting the multi-month timeline needed to observe stable weight and hepatic fat endpoints.
Related compounds
Further reading
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.